Perspective Therapeutics, Inc. (CATX)
D
Pipeline Grade
Financial Position (from SEC Filings)
$59.1M
Cash & Equivalents
$31.5M
Quarterly Burn Rate
6 mo
Est. Cash Runway
$343M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-08-01 | Phase3 Readout | — |
| 2026-10-29 | Phase3 Readout | — |
| 2026-12-31 | Phase2 Readout | — |
Active Clinical Trials (38)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06195423 | Stopping OsteoARthritis After an ACL Tear | OTHER | Recruiting | 210 |
| NCT07642856 | Individualized Neuro-Modulation Paired With Cerebellar Therapy | OTHER | Recruiting | 30 |
| NCT03887715 | A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Thera... | OTHER | Recruiting | 6,800 |
| NCT07164378 | International Study of the SING IMT™ Prosthesis in Pseudophakic patiEnts With Stable Moderate to Profound Bilateral Ce... | OTHER | Recruiting | 44 |
| NCT04458831 | A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or R... | OTHER | Active Not Recruiting | 583 |
| NCT07292961 | Investigating the Effectiveness of the Biopsychosocial Model-Based Exercise Approach in Children and Adults Diagnosed Wi... | OTHER | Recruiting | 48 |
| NCT07115030 | Project STRONGER: Stepped Care for Opioid Use Disorder Treatment Engagement and Recovery | OTHER | Recruiting | 532 |
| NCT06820528 | Trapeziectomy and Suture Suspensionplasty for Thumb Carpometacarpal Arthritis - Is In-Clinic Therapy Needed? | OTHER | Recruiting | 180 |
| NCT05858268 | NeuralNET Cerebral Palsy Pilot Study | OTHER | Active Not Recruiting | 66 |
| NCT06757712 | Periodization Resistance Training on Quality of Life in Females With Hypothyroidism | OTHER | Recruiting | 75 |
| NCT06857942 | A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Pa... | PHASE4 | Recruiting | 200 |
| NCT07012070 | Improving Walking Performance in Patients With Peripheral Artery Disease Through Wearable Activity Trackers | OTHER | Recruiting | 70 |
| NCT07417137 | A Natural History Study of Angelman Syndrome | OTHER | Recruiting | 40 |
| NCT04294134 | MIO-CPP to Improve the Well-being, Permanency, and Safety Outcomes for Young Children at Risk of or in Out-of-home Place... | OTHER | Enrolling By Invitation | 320 |
| NCT04792528 | REACT MCI - Repeated Advanced Cognitive Training in Mild Cognitive Impairment | OTHER | Active Not Recruiting | 205 |
| NCT03797495 | Study of Individuals Affected With Hypoplasminogenemia | OTHER | Recruiting | 100 |
| NCT06624930 | Behaviour Change for Cancer Survivors Trial | OTHER | Recruiting | 236 |
| NCT04239573 | Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers | OTHER | Recruiting | 770 |
| NCT07491484 | Impact of Physical Functioning on Patient-Reported Outcomes in ALS Patients at TidalHealth | OTHER | Recruiting | 30 |
| NCT06149286 | A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Len... | PHASE3 | Recruiting | 470 |
| NCT05561387 | Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Me... | PHASE3 | Recruiting | 510 |
| NCT03233191 | Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer | PHASE3 | Active Not Recruiting | 108,508 |
| NCT03769506 | ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of... | PHASE3 | Active Not Recruiting | 135 |
| NCT06914609 | REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome | PHASE3 | Recruiting | 158 |
| NCT04936308 | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha A... | PHASE3 | Active Not Recruiting | 453 |
| NCT07207811 | CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in Peop... | PHASE3 | Recruiting | 1,280 |
| NCT05317416 | Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant | PHASE3 | Active Not Recruiting | 854 |
| NCT06097364 | A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to... | PHASE3 | Active Not Recruiting | 733 |
| NCT07237256 | Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib | PHASE3 | Recruiting | 3,902 |
| NCT02107703 | A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breas... | PHASE3 | Active Not Recruiting | 669 |
| NCT03539744 | A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomid... | PHASE3 | Active Not Recruiting | 265 |
| NCT05192382 | A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2) | PHASE3 | Active Not Recruiting | 111 |
| NCT05973773 | REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) | PHASE3 | Active Not Recruiting | 285 |
| NCT02246621 | A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer | PHASE3 | Active Not Recruiting | 493 |
| NCT06182774 | Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Mu... | PHASE3 | Recruiting | 570 |
| NCT06450314 | Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests. | PHASE2 | Recruiting | 170 |
| NCT06011109 | Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab | PHASE2 | Recruiting | 30 |
| NCT05967195 | Trial to Increase FEP Attendance | PHASE1 | Active Not Recruiting | 145 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-05-22 | 8-K | Perspective Therapeutics, Inc. (CATX) (CIK 0000728387) - EX-99.1 | EDGAR |